<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03526354</url>
  </required_header>
  <id_info>
    <org_study_id>14611</org_study_id>
    <nct_id>NCT03526354</nct_id>
  </id_info>
  <brief_title>Brexpiprazole Study</brief_title>
  <official_title>A Multi-center, Randomized, Controlled Trial of Brexpiprazole for the Treatment of Co-occurring Schizophrenia and Substance Use Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Massachusetts, Worcester</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of North Carolina, Chapel Hill</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Otsuka Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Massachusetts, Worcester</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The proposed study is a 3-site, 12-week, novel, feasibility, investigation of patients who
      have co-occurring diagnoses of schizophrenia and current substance use disorder (alcohol,
      cocaine, heroin, or cannabis). Eighty patients will be randomly assigned to switch to
      brexpiprazole (the brexpiprazole group) or remain on the same antipsychotic treatment (the
      control group). The study will be conducted at 3 sites in the US. The investigators expect to
      enroll 80 subjects across 3 sites. UMass Medical School, Worcester MA is the lead site.
      Sub-sites include Massachusetts General Hospital (MGH) and the University of North Carolina
      at Chapel Hill (UNC).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      STUDY OBJECTIVES

      The primary objectives of the study include:

        1. examine the effect of brexpiprazole treatment on the number of days of substance use in
           the past week as measured by the Timeline Follow-Back (TLFB) assessment;

        2. examine the effect of brexpiprazole treatment on substance craving using 100-mm visual
           analogue scale (VAS).

      The secondary objectives are to examine the effect of brexpiprazole treatment on:

        1. the dollar amount spent on substances in the past week;

        2. the psychiatric symptoms as measured using PANSS
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 19, 2018</start_date>
  <completion_date type="Anticipated">September 19, 2020</completion_date>
  <primary_completion_date type="Anticipated">March 19, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time line Follow back (TLFB)</measure>
    <time_frame>12 weeks</time_frame>
    <description>to measure weekly substance us</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Visual Analog Scale</measure>
    <time_frame>12 weeks</time_frame>
    <description>measure to assess carving for substances</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Schizophrenia</condition>
  <condition>Schizoaffective Disorder</condition>
  <condition>Substance Use Disorders</condition>
  <arm_group>
    <arm_group_label>Experimental</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Brexpiprazole 4mg daily for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment as Usual</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Stay on current antipsychotic medication for 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Brexpiprazole</intervention_name>
    <description>Brexpiprazole 4mg daily for 12 weeks</description>
    <arm_group_label>Experimental</arm_group_label>
    <other_name>Study Medication</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Treatment as Usual</intervention_name>
    <description>Current antipsychotic medication for 12 weeks</description>
    <arm_group_label>Treatment as Usual</arm_group_label>
    <other_name>Current Antipsychotic Treatment</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age 18-65 years old

          2. Meets the DSM-5 criteria for diagnoses of schizophrenia or schizoaffective disorder
             and substance use disorder (alcohol, cocaine, heroin, or cannabis) based on the
             Structured Clinical Interview for the DSM-5 (SCID)

          3. Uses substance on at least 4 of the past 30 days prior to randomization with at least
             one use in the week prior to randomization for one of substances (cocaine, heroin,
             cannabis or alcohol) assessed by the TLFB interview

          4. Stable dose of antipsychotic agent for at least one month

          5. Well established compliance with outpatient medications

          6. Female subjects of child-bearing potential are required to practice appropriate birth
             control methods during the study.

        Exclusion Criteria:

          1. Psychiatrically unstable

          2. Currently meets DSM-5 criteria for any substance use disorder other than caffeine,
             nicotine, alcohol, cocaine, heroin and cannabis

          3. Significant, unstable medical conditions including severe cardiovascular, hepatic,
             renal or other medical diseases

          4. History of a seizure disorder

          5. Pregnancy or breastfeeding

          6. Currently on aripiprazole or cariprazine

          7. Currently on medications to treat substance use (disulfiram, naltrexone,
             acamprosate,methadone, buprenorphine, varenicline or buproprion)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xiaoduo Fan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Massachusetts, Worcester</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Joseph Mayotte, BA</last_name>
    <phone>508-856-2494</phone>
    <email>Joseph.Mayotte@umassmed.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Christopher McCain, BS</last_name>
    </contact>
    <investigator>
      <last_name>Oliver Freudenreich, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UMass Medical School</name>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <zip>01655</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joseph Mayotte, BA</last_name>
    </contact>
    <investigator>
      <last_name>Xiaoduo Fan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of North Carolina</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Fred Jarskog, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 3, 2018</study_first_submitted>
  <study_first_submitted_qc>May 15, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 16, 2018</study_first_posted>
  <last_update_submitted>May 15, 2018</last_update_submitted>
  <last_update_submitted_qc>May 15, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 16, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Massachusetts, Worcester</investigator_affiliation>
    <investigator_full_name>Xiaoduo Fan</investigator_full_name>
    <investigator_title>Associate Professor of Psychiatry</investigator_title>
  </responsible_party>
  <keyword>Schizophrenia</keyword>
  <keyword>Schizoaffective Disorder</keyword>
  <keyword>Substance Use Disorders</keyword>
  <keyword>Alcohol Use Disorder</keyword>
  <keyword>Cannabis Use Disorder</keyword>
  <keyword>Cocaine Use Disorder</keyword>
  <keyword>Heroin Use Disorder</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Schizophrenia</mesh_term>
    <mesh_term>Psychotic Disorders</mesh_term>
    <mesh_term>Substance-Related Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antipsychotic Agents</mesh_term>
    <mesh_term>Brexpiprazole</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

